Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
The combination of retatrutide and cagrilintide shows promise in enhancing weight loss and metabolic outcomes in obese male rats, but further research is needed to confirm these effects in humans.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
This study measured the effects of a combination therapy with retatrutide and cagrilintide on weight loss and metabolic outcomes in diet-induced obese male rats. The therapy produced dose-dependent reductions in body weight and food intake, surpassing the effects of equimolar monotherapies. Improvements were also observed in circulating markers of metabolic health.
Abstract
Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obese male rats. Daily co-administration produces dose-dependent reductions in body weight and food intake that exceed both equimolar monotherapies and matched-dose comparator combinations incorporating semaglutide or tirzepatide. The combination therapy also improves circulating markers of metabolic health, including cholesterol, triglycerides and insulin levels. Pair-feeding and weight-matching studies reveal that the enhanced weight loss cannot be explained by reduced food intake alone and enable discrimination between weight-loss-dependent and drug-specific molecular responses. Plasma proteomic profiling highlights enrichment of bioenergetic processes with the combination therapy, whereas brain transcriptomic profiling identifies convergent central neuronal programmes linked to energy balance regulation. Collectively, our preclinical findings support five-receptor polypharmacology as a strategy for efficaciously lowering body weight and provide guidance for the design of next-generation unimolecular multi-receptor agonists.
Background
This paper addresses the challenge of achieving maximal weight loss and metabolic control in obesity treatment, particularly for patients with obesity and type 2 diabetes. Previous studies have shown the potential of peptide multi-receptor agonists in obesity management, but there remains a need for improved strategies. This study evaluates a combination therapy involving retatrutide and cagrilintide to enhance metabolic benefits beyond existing monotherapies.
Methods
The study utilized a preclinical model involving diet-induced obese male rats. Specifics regarding the sample size, dosing regimen, and duration of the intervention were not reported in the abstract. The primary outcome measures included body weight, food intake, and metabolic markers.
Results
The combination therapy resulted in reductions in body weight and food intake that were dose-dependent. The abstract notes that these effects exceeded those of equimolar monotherapies and matched-dose comparator combinations, although specific numeric results were not provided. Improvements in circulating markers of metabolic health were also observed.
Interpretation
While the findings suggest that the combination therapy may offer enhanced benefits compared to existing treatments, the lack of specific numeric data limits the ability to assess the clinical significance of the results. The study's reliance on a rodent model raises questions about the applicability of the findings to human populations. The potential for confounding factors, such as the effects of reduced food intake, also complicates the interpretation of the results.
Key findings
- Daily co-administration produces dose-dependent reductions in body weight and food intake.
- The combination therapy exceeds both equimolar monotherapies and matched-dose comparator combinations incorporating semaglutide or tirzepatide.
- Enhanced weight loss cannot be explained by reduced food intake alone.
Limitations
- Based on preclinical evidence in rats.
- Specific numeric findings not reported in the abstract.
- Potential confounding factors not fully addressed.